The former chief medical officer at CRISPR Therapeutics has joined Takeda as head of its oncology therapeutic area unit, which saw several programmes for the disease area cut earlier this week.
Prior to joining CRISPR in May 2022, Morrow spent over a decade at Amgen, where she served as global therapeutic area head of haematology, GI oncology, GU oncology and bone diseases. Takeda noted that during her tenure, she oversaw the development and registration of several new medicines and led late-stage development for multiple other investigational therapies.
Cell therapies slashed from pipeline
Takeda also disclosed this week it has ended development of four early-stage cancer programmes, including three CAR-T cell therapies.
The most advanced was modakafusp alfa (TAK-573), a CD38-targeted immunocytokine designed to deliver interferon alpha-2b (IFNα2b). According to ClinicalTrials.gov, the candidate was being studied in a pair of Phase I/II studies to treat relapsed refractory multiple myeloma.
Takeda’s trio of axed Phase I CAR-T programmes comprise one targeting mesothelin and a second directed against GPC3 – both for solid tumours – and a Memorial Sloan Kettering Cancer Center-partnered CD19-targeted therapy for B-cell malignancies.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.